据英国《每日邮报》9月17日报道，据英国《每日邮报》9月17日报道，在一个单一中心的非小细胞肺癌患者中实施PD-L1分析。PA4678六世- 54 - 5 63 SP - PA4678盟Spyratos Dionisios g . AU - Tsiouprou Ioanna盟——Tsartsianidou瓦伦蒂娜盟——Lampaki索菲亚盟——Eleftheriadou Ellada盟——Domvri Kalliopi盟——Kontakiotis塞奥佐罗斯•Y1 - 2019/09/28 UR - //www.qdcxjkg.com/content/54/suppl_63/PA4678.abstract N2 -现在,癌症免疫治疗正在迅速发展，靶向程序性死亡1受体(PD - 1)/PD配体1 (PD - L1)途径的单克隆抗体已被批准用于NSCLC的治疗;然而，目前PD - L1分析在日常临床实践中的应用还缺乏证据。为此，我们在肺癌肿瘤科进行了一项回顾性观察研究。符合条件的患者为2017年4月至2018年12月在我科接受治疗的成年男女非小细胞肺癌患者。共123例患者使用免疫组化方法对PD - L1表达进行了研究。123例患者中，男性108例(87.8%)，平均年龄67.5±9.3岁。鳞状细胞癌52例(42.3%)，腺癌63例(51.2%)，NOS、腺鳞癌和大细胞癌8例。在123例标本中，4例不符合PD - L1免疫组化分析(100个恶性细胞/光场)。67例(54.5%)PD - L1 TPS评分<1%和20例(16%)PD - L1 TPS评分≥50%。 Also 41 patients (33.3%) were treated with anti‑PD‑1 drugs (14 as first line, 19 as second and 8 as third). Eighteen of the patients who were treated with anti‑PD‑1 drugs were initially staged as IVA (43.9%) and 7 as IVB (17.1%). 14 out of 31 patients (20.4%) had disease control (8 SD and 6 PR/CR).In this retrospective analysis we found that the percentage of patients with PD‑L1 expression ≥50% was 16% which is much lower than it was usually noticed in clinical trials. This could be probably attributed to the high percentage of patients with early or locally advanced tumors who were included.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4678.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -